The average BRAF mRNA expression was significantly higher in premenopausal patients, patients with high tumor grade, hormone receptor–negative status, and non-luminal tumors compared to postmenopausal patients, patients with low-grade, hormone receptor–positive, and luminal disease. This evidence concerns the gene NR4A1 and neoplasm.